Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+1.25%
1,110.47
+13.75
+1.25%
—1,096.721,098.741,113.821,098.74——
SIXC
Communications
SIXC
Communications
SIXC
-1.19%
604.07
-7.25
-1.19%
—611.32611.32611.32603.33——
SIXE
Energy
SIXE
Energy
SIXE
+2.56%
1,201.49
+29.95
+2.56%
—1,171.541,176.151,202.381,176.15——
SIXI
Industrials
SIXI
Industrials
SIXI
+1.01%
1,765.30
+17.67
+1.01%
—1,747.631,747.671,770.511,744.43——
SIXM
Financials
SIXM
Financials
SIXM
-0.17%
630.42
-1.07
-0.17%
—631.49631.23633.90627.95——
SIXR
Staples
SIXR
Staples
SIXR
-1.00%
841.45
-8.49
-1.00%
—849.94850.23850.23836.20——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.35%
218.83
+0.77
+0.35%
—218.06218.06219.96218.02——
SIXT
Technology
SIXT
Technology
SIXT
+1.31%
3,582.23
+46.20
+1.31%
—3,536.033,549.423,590.523,543.38——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.97%
913.89
+8.82
+0.97%
—905.07908.07916.83907.68——
SIXV
Health care
SIXV
Health care
SIXV
-0.38%
1,444.33
-5.53
-0.38%
—1,449.861,451.341,464.451,440.75——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.72%
2,412.96
-17.51
-0.72%
—2,430.472,415.842,422.952,396.14——
Q1 2026 earnings • released • EPS met 0.00% • Revenue beat +115.69%
See results
LXRX:NASDAQ
Lexicon Pharmaceuticals Inc
$2.31
+15.50%
(+0.31) 1D
$2.30
-0.43% (-0.0100)
Pre-market
Closed: May 11, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LXRX...
Open
$2.01
High
$2.47
Low
$2.00
Mkt. cap
1.03B
Avg. vol.
2.17M
Volume
12.21K
52-wk high
$2.47
52-wk low
$0.51
EPS
-$0.14
Beta
1.27
Shares outstanding
444.20M
No. of employees
81
News stories
From sources across the web
Profile
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology. The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
About Lexicon Pharmaceuticals Inc
CEOLonnel Coats
Employees81
Founded1995
Headquarters-
SectorPharmaceutical industry
Websitelexpharma.com
Last report
May 7, 2026
Fiscal Period
Q1 2026
EPS / Est. (USD)
/ -$0.04
0.00%miss
Revenue / Est. (USD)
21.10M / 9.78M
+115.69%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
28.87M
14.18M
5.49M
21.10M
Cost of goods sold
1.65M
18.77M
-43.32M
108.00K
Cost of revenue
1.65M
18.77M
-43.32M
108.00K
Research and development expenses
14.13M
-
54.83M
12.76M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.35M
7.60M
8.76M
9.23M
Operating expense
23.48M
7.60M
63.59M
21.99M
Total operating expenses
25.13M
26.37M
20.27M
22.10M
Operating income
3.74M
-12.19M
-14.78M
-996.00K
Other non operating income
-
-
-
-
EBT including unusual items
3.25M
-12.77M
-15.53M
-1.04M
EBT excluding unusual items
3.25M
-12.77M
-15.53M
-1.04M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
3.25M
-12.77M
-15.53M
-1.04M
Net profit margin
11.27%
-90.04%
-282.72%
-4.94%
Earnings per share
0.01
-0.04
-0.04
-
Interest and investment income
1.83M
1.57M
1.28M
1.54M
Interest expense
-2.32M
-2.16M
-2.03M
-1.59M
Net interest expenses
-484.00K
-582.00K
-750.00K
-47.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
3.91M
-12.04M
-14.66M
-840.75K
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer